All In Biotech

Drug Trial Radar · NCT04410133

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy

Last checked: Nov 20, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

151

Actual

Start

Oct 26, 2020

Primary completion

Jun 5, 2023

Study completion Jun 5, 2023

Sponsor

Lead sponsor
Blue Earth DiagnosticsIndustry
Sponsor type
Industry
Collaborators
Precision For Medicine
First posted
Jun 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy

Conditions

  • Brain Metastases

Interventions

  • 18F fluciclovineDrug

    18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject LevelTime frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • University of California, San Francisco

    San Francisco, California

  • John Wayne Cancer Institute at Providence St. John's Health Center

    Santa Monica, California

  • Yale School of Medicine

    New Haven, Connecticut

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida

  • Medical College of Georgia, Augusta University

    Augusta, Georgia

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Washington University School of Medicine-Center for Clinical Imaging Research

    St Louis, Missouri

  • NYU Langone Health

    New York, New York

  • University Hospital Cleveland

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Pennsylvania Health System

    Philadelphia, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Center for Quantitative Cancer Imaging at Huntsman Cancer Institute

    Salt Lake City, Utah

  • West Virgina University Cancer Institute

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.